Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1)
Pseudomonas Aeruginosa Infectious Disease
BiomX Ltdother_biologicalPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Pseudomonas Aeruginosa Infectious Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ap-Pa02 Armata Pharmaceuticals, Inc. | Phase 2 | BB |
Aztreonam Lysine Gilead Sciences | Phase 3 | BB |
Ceftolozane Sunshine Coast Hospital and Health Service | Phase 4 | BB |
Piperacillin Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | BB |
Tazobactam Sunshine Coast Hospital and Health Service | Phase 4 | BB |
View all 12 →
Same molecule, other indications
Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →